Αποτελέσματα Αναζήτησης
8 Μαΐ 2018 · The USPSTF recommends against PSA-based screening for prostate cancer in men 70 years and older and suggests shared decision making for men 55 to 69 years. The recommendation considers the benefits and harms of screening, the risk factors, the screening tests, and the treatment options for prostate cancer.
21 Δεκ 2023 · The Task Force is updating its recommendation on prostate cancer screening based on new evidence. See the current final recommendation, the draft research plan, and the opportunity for public comment.
21 Δεκ 2023 · What are the benefits of prostate specific antigen (PSA)-based screening for prostate cancer vs. no screening or usual care on short- or long-term prostate cancer mortality, incidence of metastatic prostate cancer, all-cause mortality, quality of life, and function?
27 Αυγ 2024 · Learn about the USPSTF guidelines for prostate cancer screening, which vary by age and risk factors. Consider the benefits and harms of screening, diagnosis, and treatment before making a decision with your doctor.
The USPSTF grade C recommendation for prostate cancer screening 3 has restarted a national discussion on prostate cancer early detection. The Task Force deserves credit for this more balanced, fairer approach.
8 Μαΐ 2018 · Objective: To update the 2012 US Preventive Services Task Force (USPSTF) recommendation on prostate-specific antigen (PSA)-based screening for prostate cancer. Evidence review: The USPSTF reviewed the evidence on the benefits and harms of PSA-based screening for prostate cancer and subsequent treatment of screen-detected prostate cancer.
17 Ιουλ 2012 · Methods: The USPSTF reviewed new evidence on the benefits and harms of prostate-specific antigen (PSA)-based screening for prostate cancer, as well as the benefits and harms of treatment of localized prostate cancer.
